MosaiQ® Abstract Presented at APLAR 2023

At AliveDx, we understand that the success of our business is closely linked to the wellbeing of the communities in which we operate. Our goal is to advance sustainable practices in every aspect of our operations. We are pleased to

AliveDx Suisse S.A. and Ozgun Kimya A.S. have signed a distribution agreement, which will enable Ozgun Kimya A.S. to distribute the MosaiQ® solution in Türkiye. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s consistent commitment to grow

We are excited to announce that our recently CE-marked MosaiQ® AiPlex CTD microarray immunoassay, which aims to shorten time-to-diagnosis for autoimmune patients, is now available in over 35 markets across Europe and the Asia Pacific region. The MosaiQ AiPlex CTD

Our leadership team recently gathered to celebrate 2023 achievements and kick off the new year. As part of a highly energizing team-building activity, and to bring our environmental, social and governance commitments to life, the team built solar lamps that

We are excited to share that our publication on the performance characteristics of our automated planar microarray immunoassay for the detection of antibodies against Centromere Protein B is now available in Immunochemistry & Immunopathology: https://www.hilarispublisher.com/open-access/performance-characteristics-of-a-novel-fully-automated-planar-microarray-immunoassay-for-the-detection-of-antibodies-against-centr-103431.html Would you like to know

AliveDx and Global Marketing Services (GMS) have signed distribution agreements, which will enable Global Marketing Services to distribute MosaiQ® and Alba products in Pakistan. The distribution agreements take effect immediately. This strategic partnership acts as a reminder of AliveDx’s commitment